Table 2 Retrospective SPC results (Good control level) at week 12
Study | Treatment Group | Safe Psoriasis Control (SPC)* |
|---|---|---|
ACD2058[14] | Placebo (n = 170) | 18 (10.6 %) |
| Â | Efalizumab 1.0 mg/kg/wk (n = 162) | 75 (46.3 %) |
ACD2059[13] | Placebo (n = 122) | 12 (9.8 %) |
| Â | Efalizumab 1.0 mg/kg/wk (n = 232) | 86 (37.1 %) |
ACD2390[12] | Placebo (n = 187) | 20 (10.7 %) |
| Â | Efalizumab 1.0 mg/kg/wk (n = 369) | 140 (37.9 %) |
Pooled studies | Placebo (n = 479) | 50 (10.4%) |
| Â | Efalizumab 1.0 mg/kg/wk (n = 763) | 301 (39.4%) |